Abstract
Undoubtedly, the war on cancer is an expensive endeavour. It is estimated that, where data are available in Europe (e.g. Germany and France), cancer care accounts for a similar proportion of overall health-care expenditure to that in the USA, i.e. approximately 5%. Currently, no society can afford all of the potential cancer treatments for all the patients that could benefit from them. How the required resources should be provided is one of the great on-going debates, and different countries approach this problem in different ways. Additionally, the more we understand about the pathology, pathogenesis, diagnosis and treatment of cancer, the more options are created. Many of these options are new diagnostic tools and more effective treatments. Obviously these innovations, paired with an increasing patient pool, are leading to tremendous health-care expenditures,well surpassing current budgets. Hence, the question arises of how many resources should be devoted to the management of cancers, given that resources are scarce and many other fields and specialities are competing for these resources. This paper addresses the question of whether preventive measures in oncology eventually pay off.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hartmann M, Kath R, Gundermann C (2008)Oncological resource allocation in Germany.Onkologie 31:85–89
Drummond MF, O'Brien B, Stoddart GL,Torrance GW (1997) Methods for the evaluation of health care programs, 2nd edn. Oxford Medical Publications, Oxford
Weinstein MC (1996) From cost-effectiveness ratios to resource allocation: where to draw theline? In: Sloan FA (ed) Valuing health care.Cambridge University Press, Cambridge
Tengs T (2000) One thousand quality-of life estimates. Med Care 38:592–637
Cohen JT, Neumann PJ, Weinstein MC (2008) Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 358:661–663
Russell LB (2007) Prevention's potential for slowing the growth of medical spending. Institute for Health, Health Care Policy and Aging Research, Rutgers University. http://www.nchc.org/nchc_report.pdf. Cited 12 Apr 2008
Neeser K, Szucs T, Bulliard JL, Bachmann G,Schramm W (2007) Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health 10:42–53
Christie D (1977) Screening for breast cancer: the role of mammography. Med J Aust 2:398–400
Eddy DM, Hasselblad V, McGivney W, Hendee W (1988) The value of mammography screening in women under age 50 Years. JAMA 259:1512–1519
Kristein MM (1977) Economic issues in prevention. Prev Med 6:252–264
Khandker RK, Dulski JD, Kilpatrick JB, Ellis R P, Mitchell JB, Baine WB (2000) A decision model and cost-effectiveness analysis of color-ectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 16:799–810
Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (1954) Cost-effectiveness of screening for color-ectal cancer in the general population. JAMA 284:1954–1961
Fahs MC, Mandelblatt J, Schechter C, Muller C (1992) Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117:520–527
Doggett DL, Mitchell MM, Tappe KA, Turkelson CW (2000) Prostate cancer screening with PSA:a Markov process cost-effectiveness decision analysis. Annu Meet Int Soc Technol Assess Health Care.Int Soc Technol Assess Health Care Meet 16:356
Kramer BS, Brown ML, Prorok PC, Potosky AL,Gohagan JK (1993) Prostate cancer screening:what we know and what we need to know. Ann Intern Med 119:914–919
Losina E, Walensky R P, Geller A, Beddingfield FC 3rd, Wolf LL, Gilchrest BA, Freedberg KA (2007) Visual screening for malignant melanoma:a cost-effectiveness analysis. Arch Dermatol 143:21–28
Szucs TD, Wyss P, Dedes KJ (2003) Cost-effectiveness studies in ovarian cancer. Int J Gynecol Cancer 13[Suppl 2]:212–219
Szucs TD, Largeron N, Dedes KJ, Rafia R,Benard S (2008) Cost-effectiveness analysis of adding a quadrivalent HPV Vaccine to the cervical cancer screening programme in Switzerland Curr Med Res Opin 24:1473–1483
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Szucs, T.D., Dedes, K.J. (2009). Is Cancer Prevention Ever Going to Be Profitable?. In: Senn, HJ., Kapp, U., Otto, F. (eds) Cancer Prevention II. Recent Results in Cancer Research, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69297-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-540-69297-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69296-6
Online ISBN: 978-3-540-69297-3
eBook Packages: MedicineMedicine (R0)